ApoPharma clinical trials

Acquired by Chiesi Farmaceutici S.p.A.

The registry lists 23 studies whose lead sponsor is ApoPharma. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 10, 2024.

Studies

Recruiting first, then most recently updated. Showing 23 of 23. All Chiesi Farmaceutici S.p.A. studies →

• Study of Parkinson's Early Stage With DeferiproneCompletedNCT02728843Phase 2

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other AnemiasTerminatedNCT02443545Phase 4

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other AnemiasTerminatedNCT02041299Phase 4

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron OverloadCompletedNCT03802916Phase 2

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated NeurodegenerationCompletedNCT02174848Phase 3

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)CompletedNCT01741532Phase 3

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive SubjectsCompletedNCT02456558Phase 1

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Pilot Study of the Pharmacokinetic Profile of Deferiprone Sustained-Release Formulation in Healthy VolunteersCompletedNCT02189941Phase 1

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy VolunteersCompletedNCT02442310Phase 1

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy VolunteersCompletedNCT02465489Phase 1

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Efficacy Study in Removing Excess Iron From the HeartCompletedNCT00105495Phase 4

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell DiseaseCompletedNCT01835496Phase 1

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT01483924Phase 2

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy VolunteersCompletedNCT01989455Phase 1

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Evaluation of Whether Deferiprone Affects QT Interval in Healthy SubjectsCompletedNCT01860703Phase 4

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy VolunteersCompletedNCT01767103Phase 4

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal ImpairmentCompletedNCT01770652Phase 4

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected SubjectsCompletedNCT02191657Phase 1

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Active Drug Surveillance Program of Ferriprox UseCompletedNCT01838291

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's AtaxiaCompletedNCT00897221Phase 2

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's AtaxiaCompletedNCT00530127Phase 1/2

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric PatientsCompletedNCT00529152Phase 3

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group

• Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot UlcersTerminatedNCT00387101Phase 3

  Sponsor listed in the registry: ApoPharma · ApoPharma — acquired company within the Chiesi Farmaceutici S.p.A. group